ANAB compared with ZYME: revenue, margins and what each company keeps, and the suppliers and customers both name

ANABAnaptysbio, Inc

Mkt capRevenueRevenue

ZYMEZymeworks Inc.

Mkt capRevenueRevenue

Compare

ANABAnaptysbio, Inc

ZYMEZymeworks Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

ANABAnaptysbio, Inc

47.32▼−1.99%

Mkt cap$1.4BRevenue$26MQ1 FY26Revenue$235MFY25

ZYMEZymeworks Inc.

28.99▲+1.31%

Regular sessionNov 2 '26

Mkt cap$2.1BRevenue$5MQ2 FY26Revenue$106MFY25

Compare

Regular sessionNov 2 '26

ANABAnaptysbio, Inc

ZYMEZymeworks Inc.

47.32▼−1.99%

Price

28.99▲+1.31%

$1.4B

Mkt cap

$2.1B

Q1 FY26$26M

Revenue

$5MQ2 FY26

FY25$235M

Revenue

$106MFY25

ANAB47.32▼−1.99%vsZYME28.99▲+1.31%Regular sessionNov 2 '26

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

ANAB: latest quarter is a loss; flow not drawable. ZYME: latest quarter is a loss; flow not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only ANAB 4

VNDAVanda Pharmaceuticalscustomer

GSKGSKcustomer

—DRI Healthcare Trustunlistedsupplier

—Sagard Healthcare Royalty Partnersunlistedsupplier

Shared 0

No shared counterparties.

Only ZYME 11

JNJJ&Jcustomer

BMYCelgene (now BMS)customer

JAZZJazz Pharmaceuticals Irelandcustomer

RPRXRoyalty Pharmacustomer

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

7 more · ZYME chain ›

Price

rebased to 0%

ANAB, solidZYME, dashed